Cadrenal Therapeutics (CVKD) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Cadrenal Therapeutics (CVKD) is Strong Underperform.

The composite score behind that read is -0.54, weighing +0.00 of bullish evidence against -0.54 bearish.

Cadrenal Therapeutics last closed at $0.99, +4.21% on the session.

Against the IVW growth benchmark the position is +3.60% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

17 graded predictions for CVKD so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Cadrenal Therapeutics in the 2nd percentile on return on equity, where 100 is best.

Cadrenal Therapeutics is classified under Health Care / Pharmaceuticals, with a market capitalisation of $3.37M.

StockMap tracks Cadrenal Therapeutics as the 134th largest of the 142 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 61 Moderate Underperform, 57 Neutral, 19 Strong Underperform and 5 Moderate Outperform.

On that composite Cadrenal Therapeutics ranks 129th of 142 in the group, against a group median of -0.24.